Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy.

Autor:	Chakraborty R; Columbia University Medical Center, New York, New York, United States., Zanwar S; Mayo Clinic, rochester, Minnesota, United States., Hegenbart U; University Hospital, Heidelberg, Germany., Bhutani D; Columbia University, College of Physicians and Surgeons, New York, New York, United States., Gertz MA; Mayo Clinic, Rochester, Minnesota, United States., Dispenzieri A; Mayo Clinic, Rochester, Minnesota, United States., Kumar SK; Mayo Clinic, Rochester, Minnesota, United States., D'Souza A; Medical College of Wisconsin, Milwaukee, Wisconsin, United States., Patwari A; Medical college of Wisconsin, Milwaukee, Wisconsin, United States., Cowan AJ; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, United States., Chen G; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, United States., Milani P; Amyloidosis Research and Treatment Center, Pavia, Italy., Palladini G; University of Pavia and Foundation IRCCS Policlinico San Matteo, Pavia, Italy., Sanchorawala V; Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States., Bodanapu G; Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, United States., Schönland S; University of Heidelberg, Heidelberg, Germany., Lentzsch S; Columbia University Medical Center, New York, New York, United States., Muchtar E; Mayo Clinic, Rochester, Minnesota, Rochester, Minnesota, United States.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2024 Aug 28. Date of Electronic Publication: 2024 Aug 28.
DOI:	10.1182/blood.2024025899
Abstrakt:	We performed an international retrospective cohort study to investigate the prognostic impact of cytogenetic abnormalities by FISH in 283 patients with AL amyloidosis treated with frontline daratumumab-bortezomib-cyclophosphamide-dexamethasone (Dara-VCD) or Dara-VD. The cytogenetic subgroups of interest were t(11;14), gain/amp(1q) [hereafter, +1q], hyperdiploidy, deletion(13q), del(17p), and myeloma high-risk (HR) translocations (t[4;14], t[14;16], or t[14;20]). The endpoints of interest were rate of hematologic complete response (heme CR), very good partial response or better (≥VGPR), and hematologic event-free survival (Heme EFS). The incidence of abnormalities was following: t(11;14)-53.4%; deletion (13q)-28.9%; +1q-22.3%; hyperdiploidy-19.4%; HR translocations-6.6%; and deletion(17p)-4.5%. The heme-CR rate by cytogenetic subgroups were: t(11;14) vs no t(11;14)-45.2% vs 41.8% (p=0.597); del(13q) vs no del(13q)-46.8% vs 42.8% (p=0.594); +1q vs no +1q-30.2% vs 47.9% (p=0.022); hyperdiploidy vs no hyperdiploidy-39.5% vs 44.9% (p=0.541); HR translocations vs none: 45.5% vs 43.1% (p=0.877); and del(17p) vs no del(17p)-50.0% vs 42.9% respectively (p=0.658). Similarly, +1q was the only subgroup with a significantly lower ≥VGPR rate (64.2% vs 79.0%; p=0.033). At a median follow-up of 19.8 months, the median heme-EFS was 49.6 months (95% CI, 24.7-not reached [NR]), and the 2-year OS was 80.98% (95% CI, 75.6-85.4). The presence of+1q was significantly associated with worse heme-EFS on multivariate analysis (HR 2.06, 95% CI, 1.14-3.71; p=0.017). Notably, there was no adverse prognostic impact of t(11;14) on heme EFS or OS. In conclusion, +1q is associated with worse outcome in the daratumumab-era. Clinical trials testing novel immunotherapies frontline should be enriched in +1q to further improve outcomes in this subgroup. (Copyright © 2024 American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu